Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Structure-based design of decoy chemokines as a way to explore the pharmacological potential of glycosaminoglycans.

Adage T, Piccinini AM, Falsone A, Trinker M, Robinson J, Gesslbauer B, Kungl AJ.

Br J Pharmacol. 2012 Nov;167(6):1195-205. doi: 10.1111/j.1476-5381.2012.02089.x. Review.

2.

Chapter 4. Interactions of chemokines with glycosaminoglycans.

Hamel DJ, Sielaff I, Proudfoot AE, Handel TM.

Methods Enzymol. 2009;461:71-102. doi: 10.1016/S0076-6879(09)05404-4.

PMID:
19480915
3.

The dependence of chemokine-glycosaminoglycan interactions on chemokine oligomerization.

Dyer DP, Salanga CL, Volkman BF, Kawamura T, Handel TM.

Glycobiology. 2016 Mar;26(3):312-26. doi: 10.1093/glycob/cwv100. Epub 2015 Nov 17.

4.

PA401, a novel CXCL8-based biologic therapeutic with increased glycosaminoglycan binding, reduces bronchoalveolar lavage neutrophils and systemic inflammatory markers in a murine model of LPS-induced lung inflammation.

Adage T, del Bene F, Fiorentini F, Doornbos RP, Zankl C, Bartley MR, Kungl AJ.

Cytokine. 2015 Dec;76(2):433-41. doi: 10.1016/j.cyto.2015.08.006. Epub 2015 Aug 21.

PMID:
26303011
5.

Regulation of protein function by glycosaminoglycans--as exemplified by chemokines.

Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE.

Annu Rev Biochem. 2005;74:385-410. Review.

PMID:
15952892
6.

Designing a mutant CCL2-HSA chimera with high glycosaminoglycan-binding affinity and selectivity.

Gerlza T, Winkler S, Atlic A, Zankl C, Konya V, Kitic N, Strutzmann E, Knebl K, Adage T, Heinemann A, Weis R, Kungl AJ.

Protein Eng Des Sel. 2015 Aug;28(8):231-40. doi: 10.1093/protein/gzv025. Epub 2015 May 11.

PMID:
25969511
7.

Small molecule inhibitors of protein interaction with glycosaminoglycans (SMIGs), a novel class of bioactive agents with anti-inflammatory properties.

Harris N, Kogan FY, Il'kova G, Juhas S, Lahmy O, Gregor YI, Koppel J, Zhuk R, Gregor P.

Biochim Biophys Acta. 2014 Jan;1840(1):245-54. doi: 10.1016/j.bbagen.2013.09.023. Epub 2013 Sep 21.

PMID:
24060749
8.

Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses.

Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ, Wells TN.

Biochemistry. 1999 Sep 28;38(39):12959-68.

PMID:
10504268
9.

Characterization of the interactions of vMIP-II, and a dimeric variant of vMIP-II, with glycosaminoglycans.

Zhao B, Liwang PJ.

Biochemistry. 2010 Aug 24;49(33):7012-22. doi: 10.1021/bi100549y.

10.

The Anti-inflammatory Protein TSG-6 Regulates Chemokine Function by Inhibiting Chemokine/Glycosaminoglycan Interactions.

Dyer DP, Salanga CL, Johns SC, Valdambrini E, Fuster MM, Milner CM, Day AJ, Handel TM.

J Biol Chem. 2016 Jun 10;291(24):12627-40. doi: 10.1074/jbc.M116.720953. Epub 2016 Apr 4.

11.

Molecular engineering of glycosaminoglycan chemistry for biomolecule delivery.

Miller T, Goude MC, McDevitt TC, Temenoff JS.

Acta Biomater. 2014 Apr;10(4):1705-19. doi: 10.1016/j.actbio.2013.09.039. Epub 2013 Oct 9. Review.

12.

Chemokine-glycosaminoglycan binding: specificity for CCR2 ligand binding to highly sulfated oligosaccharides using FTICR mass spectrometry.

Yu Y, Sweeney MD, Saad OM, Crown SE, Hsu AR, Handel TM, Leary JA.

J Biol Chem. 2005 Sep 16;280(37):32200-8. Epub 2005 Jul 20. Erratum in: J Biol Chem. 2005 Dec 9;280(49):41124. Hsu, Andro R [added].

13.

The effect of the decoy molecule PA401 on CXCL8 levels in bronchoalveolar lavage fluid of patients with cystic fibrosis.

McElvaney OJ, O'Reilly N, White M, Lacey N, Pohl K, Gerlza T, Bergin DA, Kerr H, McCarthy C, O'Brien ME, Adage T, Kungl AJ, Reeves EP, McElvaney NG.

Mol Immunol. 2015 Feb;63(2):550-8. doi: 10.1016/j.molimm.2014.10.013. Epub 2014 Nov 2.

PMID:
25453468
14.

Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention.

Johnson Z, Proudfoot AE, Handel TM.

Cytokine Growth Factor Rev. 2005 Dec;16(6):625-36. Epub 2005 Jun 28. Review.

PMID:
15990353
15.

New targets for glycosaminoglycans and glycosaminoglycans as novel targets.

Gesslbauer B, Theuer M, Schweiger D, Adage T, Kungl AJ.

Expert Rev Proteomics. 2013 Feb;10(1):77-95. doi: 10.1586/epr.12.75. Review.

PMID:
23414361
16.

Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function.

Salanga CL, Handel TM.

Exp Cell Res. 2011 Mar 10;317(5):590-601. doi: 10.1016/j.yexcr.2011.01.004. Epub 2011 Jan 9. Review.

17.

Structural basis for oligomerization and glycosaminoglycan binding of CCL5 and CCL3.

Liang WG, Triandafillou CG, Huang TY, Zulueta MM, Banerjee S, Dinner AR, Hung SC, Tang WJ.

Proc Natl Acad Sci U S A. 2016 May 3;113(18):5000-5. doi: 10.1073/pnas.1523981113. Epub 2016 Apr 18.

18.

Kinetics of chemokine-glycosaminoglycan interactions control neutrophil migration into the airspaces of the lungs.

Tanino Y, Coombe DR, Gill SE, Kett WC, Kajikawa O, Proudfoot AE, Wells TN, Parks WC, Wight TN, Martin TR, Frevert CW.

J Immunol. 2010 Mar 1;184(5):2677-85. doi: 10.4049/jimmunol.0903274. Epub 2010 Feb 1.

19.

Glycosaminoglycan (GAG) binding surfaces for characterizing GAG-protein interactions.

Robinson DE, Buttle DJ, Short RD, McArthur SL, Steele DA, Whittle JD.

Biomaterials. 2012 Feb;33(4):1007-16. doi: 10.1016/j.biomaterials.2011.10.042. Epub 2011 Nov 9.

PMID:
22079008
20.

Determination of chemokine-glycosaminoglycan interaction specificity.

Kawashima H.

Methods Enzymol. 2006;416:254-63.

PMID:
17113871

Supplemental Content

Support Center